Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
about
Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug developmentAgomelatine: The evidence for its place in the treatment of depressionAdjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label studyEmerging targets for antidepressant therapiesTreating insomnia improves mood state, sleep, and functioning in bipolar disorder: a pilot randomized controlled trialNovel targets for antidepressant therapiesA systematic review of agomelatine-induced liver injuryAgomelatine in the treatment of major depressive disorder: an assessment of benefits and risksAgomelatine beyond borders: current evidences of its efficacy in disorders other than major depressionInsomnia comorbid to severe psychiatric illnessSleep disturbance in mental health problems and neurodegenerative diseaseAgomelatine in unipolar depression in clinical practice: a retrospective chart reviewCurrent and emerging therapies for the management of bipolar disordersNew therapeutic targets for mood disordersPromising avenues of therapeutics for bipolar illnessBipolar disorder: candidate drug targets.Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adultsA benefit-risk assessment of agomelatine in the treatment of major depression.Bipolar disorder with seasonal pattern: clinical characteristics and gender influencesNew targets for rapid antidepressant action.Agomelatine treatment of major depressive disorder.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.Treating each and every depressed patient.Agomelatine, a melatonin agonist with antidepressant properties.Melatonin receptor agonists: new options for insomnia and depression treatment.New drugs for bipolar disorder.Role of melatonin in mood disorders and the antidepressant effects of agomelatine.Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review.Novel biomarkers for bipolar disorder.Novel routes to bipolar disorder drug discovery.Agomelatine in depression.Sleep- and circadian rhythm-associated pathways as therapeutic targets in bipolar disorder.The use of agomelatine in OCD: effects on the motivational aspects and dysregulated circadian rhythms.Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients.Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression.Emerging drugs for bipolar disorder.Mitochondrial Agents for Bipolar Disorder.Therapeutic potential of melatonin agonists
P2860
Q22241837-9E2DBFDD-C812-4588-BEDD-07828885B58AQ24617019-B4052CD8-42F1-4D74-89D3-6EF15F546FFCQ24619584-BA8C7983-611F-4CB0-B063-55B15C2E6FE1Q28247614-57D8B8F0-4604-4D82-B83A-7F942F9DC0E2Q28646967-2EB0F52F-74D2-4844-B63B-2AEC9BAFE72AQ28648254-D4084D57-4C20-4779-B948-CB0D63C4A87BQ28648515-466F56B7-9798-4E39-9220-FAADFAE8A4F9Q28651497-3B27091C-95FA-4320-9FA1-6C09D02CC6ECQ28651498-152A29DE-DF56-4C03-A1A5-A10C5B1A4A89Q28654986-9D6121A7-1D32-440C-B06A-FE7271E001F7Q28681847-91BBE0AB-108B-4826-90B3-83A39502EDB1Q28686885-6E7427B9-BAAA-4B1F-9026-DFF9DF7A097AQ28686902-EBA7AAA1-DE84-46D9-83AB-CF8A5795BE56Q28743068-285A7B5B-E52F-4D97-A294-40219A639C09Q28744502-E753907F-C87C-4C3B-B196-02B9BFAD8236Q28751133-F1540C63-16B9-46BC-A214-2F76FB1BC65BQ28764080-BE6AA42D-B787-4FD6-8F1D-92D7B83D9D2BQ34207131-277D8547-73F5-4AF8-AFEB-5EC5958208A6Q34362981-AC066D24-2D16-4B90-A720-5481BAB0C1B8Q34507177-41018FF7-B950-48F1-A2F7-AD789FB5CDB1Q34600886-61EE81B4-4063-4F85-B6B1-DE15175A6882Q35862776-72085E82-470B-4AE6-8428-20580B43131AQ37254743-00F5B3AC-2CCF-40A8-A932-912901424B47Q37598264-F6B6EA85-B9FF-47BD-AE09-BE14525AB472Q37873581-30B3EB3D-771F-4663-A3A8-34D5EF1B4652Q37923845-85A811B2-DE8A-4F0E-A297-9F2BDF20CEB2Q38033191-A6657053-9D50-48E3-9B80-48E5D46AC079Q38093228-B4128C24-0510-4262-9CC0-06C68E39A9FAQ38093255-191A8C98-1E95-4883-BF0E-BCF1BFD4006AQ38109244-A813F69F-5D2F-481F-9195-8C8C5F580721Q38137187-9A38153A-EB8D-4259-83C2-24D6BFA07330Q38366298-FF46FCAA-6826-4476-B870-5F2DA97F1131Q38366416-BB9D25B8-5AE3-475E-87A9-B2F105D082BAQ38876395-197D985B-B6EA-4192-BA4D-34EEBD20DE4EQ48195966-D1AE921A-96EB-4C4F-86A0-A10189E2B268Q51850966-E22118D7-7265-4B34-94FE-67F67FADE16CQ52621890-FB916757-135E-4AB0-8591-4E95FEF37BB4Q58425005-0F300163-A0A1-4778-9225-D530122CDDBC
P2860
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
@ast
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
@en
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
@nl
type
label
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
@ast
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
@en
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
@nl
prefLabel
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
@ast
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
@en
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
@nl
P2093
P2860
P1433
P1476
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
@en
P2093
Catherine Perdrizet-Chevallier
Joseph R Calabrese
Julien Daniel Guelfi
P2860
P304
P356
10.1111/J.1399-5618.2007.00507.X
P407
P577
2007-09-01T00:00:00Z